🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

ICYMI: The U.S. FDA approved our unique alternative treatment shown to maintain vision in patients with diabetic macular edema. Learn more about how we’re tackling #DiabeticEyeDisease through innovative solutions: spr.ly/6017x2s4D

#Breaking: Today the New England Journal of Medicine published meaningful data from our phase III study in lupus nephritis. Learn more: gene.com/media/press-re…

#Breaking: The FDA has granted approval for the first and only tablet to treat spinal muscular atrophy (#SMA). Learn more about our new administration option: gene.com/media/press-re…

ICYMI: The first and only spinal muscular atrophy (#SMA) tablet has been granted approval by the FDA. Learn more: spr.ly/6015IlNxL

#Breaking: This #AAAAI25, we’re proud to present two late-breaking oral presentations featuring new Phase III data on our medicine for patients with food allergies. Learn more: gene.com/media/press-re…

The U.S. FDA approved our clot-dissolving agent for acute ischemic stroke in adults—the first FDA-approved #stroke medicine in nearly 30 years. This approval reinforces our long-standing dedication to advancing stroke care for patients. gene.com/media/press-re…

#Breaking: The U.S. FDA accepted our supplemental Biologics License Application for our medicine to treat #LupusNephritis based on Phase III data showing superiority over the current standard of care. Read more here: gene.com/media/press-re…

ICYMI: The U.S. FDA recently approved our clot-dissolving agent for the treatment of acute ischemic stroke (AIS) in adults. Read more: spr.ly/6016LvVwa

ICYMI: Our supplemental Biologics License Application for our anti-CD20 monoclonal antibody for lupus nephritis treatment was accepted by the U.S. FDA. Learn more: gene.com/media/press-re…

#Breaking: We’re presenting new data at #ADPD2025 showcasing advancements in our #Alzheimers research for the millions of people living with Alzheimer’s disease. Learn more: gene.com/media/press-re…

#Breaking: NEJM published a detailed analysis of positive Phase III data for our influenza treatment and household #influenza transmission. Learn more:gene.com/media/press-re… #PublicHealth #Flu

#Breaking: This #ESMOBreast25, we are excited to present ten-year follow-up data reinforcing the potential benefit of our treatment for HER2-positive early-stage breast cancer. Learn more: gene.com/media/press-re…

#Breaking: The U.S. FDA has approved our treatment in a new indication for #DiabeticRetinopathy (DR). Learn more about how this treatment offers a new alternative to the standard of care for people with DR: gene.com/media/press-re…

At #ASCO25, we will present two-year follow-up data from our Phase III study that reinforces the potential of a CD20xCD3 bispecific antibody combined with chemotherapy in relapsed or refractory diffuse large B-cell #lymphoma. Learn more: gene.com/media/press-re…

#Breaking: We’re excited to share two-year data from our investigational BTK inhibitor for people with relapsing multiple sclerosis (RMS) presented at this year’s #CMSC2025 meeting. Learn more about the results here: gene.com/media/press-re…

#Breaking: We’re presenting new survival data for PIK3CA-mutated HR+, HER2- advanced #breastcancer at #ASCO25, also published in #NEJM. Read about the results here: gene.com/media/press-re…

#Breaking at #ASCO25: We will present Phase III data, also published in The Lancet, for ES-SCLC, offering a potential option for this aggressive cancer. Learn more: gene.com/media/press-re…

#Breaking: Today we announced we will advance our investigational medicine in early #ParkinsonsDisease into Phase III development. Learn more: gene.com/media/press-re…

#Breaking: At #18ICML, we’re presenting data from our Phase III trial revealing how our novel combination therapy helped reduce the risk of disease progression for people living with large B-cell #lymphoma (#LBCL) in an outpatient setting. Learn more: gene.com/media/press-re…